Use of serologic tests in Crohn's disease

Maria T Abreu, E. A. Vasiliauskas, L. Y. Kam, M. C. Dubinsky

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Despite great progress in understanding and treating patients with Crohn's disease, the cause of this potentially debilitating disease remains elusive. Multiple studies support the hypothesis that patients with inflammatory bowel disease (IBD) have a dysregulated immune response to endogenous flora. Although we have only 2 labels for patients with IBD, Crohn's disease or ulcerative colitis (UC), these names fall short of describing the pathophysiology of these disease (Figure 1A). We now have a better understanding of the clinical, immunologic, and genetic heterogeneity that exists within "Crohn's diseases" and "ulcerative colitides." Mounting evidence suggests that IBD represents overlapping subgroups of inflammatory intestinal disorders along a continuum, with Crohn's disease and UC representing the extremes of this spectrum (Figure 1). Although the diagnosis of IBD continues to be based on clinical, endoscopic, histopathologic, and radiologic criteria, serologic markers can provide another tool to help diagnose and characterize patients with IBD. Their use is based on the hypothesis that the presence of these antibodies indicates the underlying dysregulated immune response and the environmental trigger, often bacterial, resulting in IBD (Figure 1B). This article will focus on the use of serologic tests to aid in the diagnosis and management of Crohn's disease (Table 1).

Original languageEnglish
Pages (from-to)155-164
Number of pages10
JournalClinical Perspectives in Gastroenterology
Volume4
Issue number3
StatePublished - Jan 1 2001
Externally publishedYes

Fingerprint

Serologic Tests
Inflammatory Bowel Diseases
Crohn Disease
Ulcerative Colitis
Genetic Heterogeneity
Names
Antibodies

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Abreu, M. T., Vasiliauskas, E. A., Kam, L. Y., & Dubinsky, M. C. (2001). Use of serologic tests in Crohn's disease. Clinical Perspectives in Gastroenterology, 4(3), 155-164.

Use of serologic tests in Crohn's disease. / Abreu, Maria T; Vasiliauskas, E. A.; Kam, L. Y.; Dubinsky, M. C.

In: Clinical Perspectives in Gastroenterology, Vol. 4, No. 3, 01.01.2001, p. 155-164.

Research output: Contribution to journalArticle

Abreu, MT, Vasiliauskas, EA, Kam, LY & Dubinsky, MC 2001, 'Use of serologic tests in Crohn's disease', Clinical Perspectives in Gastroenterology, vol. 4, no. 3, pp. 155-164.
Abreu MT, Vasiliauskas EA, Kam LY, Dubinsky MC. Use of serologic tests in Crohn's disease. Clinical Perspectives in Gastroenterology. 2001 Jan 1;4(3):155-164.
Abreu, Maria T ; Vasiliauskas, E. A. ; Kam, L. Y. ; Dubinsky, M. C. / Use of serologic tests in Crohn's disease. In: Clinical Perspectives in Gastroenterology. 2001 ; Vol. 4, No. 3. pp. 155-164.
@article{af1495e1a4e8441d8750f322c89a5cfd,
title = "Use of serologic tests in Crohn's disease",
abstract = "Despite great progress in understanding and treating patients with Crohn's disease, the cause of this potentially debilitating disease remains elusive. Multiple studies support the hypothesis that patients with inflammatory bowel disease (IBD) have a dysregulated immune response to endogenous flora. Although we have only 2 labels for patients with IBD, Crohn's disease or ulcerative colitis (UC), these names fall short of describing the pathophysiology of these disease (Figure 1A). We now have a better understanding of the clinical, immunologic, and genetic heterogeneity that exists within {"}Crohn's diseases{"} and {"}ulcerative colitides.{"} Mounting evidence suggests that IBD represents overlapping subgroups of inflammatory intestinal disorders along a continuum, with Crohn's disease and UC representing the extremes of this spectrum (Figure 1). Although the diagnosis of IBD continues to be based on clinical, endoscopic, histopathologic, and radiologic criteria, serologic markers can provide another tool to help diagnose and characterize patients with IBD. Their use is based on the hypothesis that the presence of these antibodies indicates the underlying dysregulated immune response and the environmental trigger, often bacterial, resulting in IBD (Figure 1B). This article will focus on the use of serologic tests to aid in the diagnosis and management of Crohn's disease (Table 1).",
author = "Abreu, {Maria T} and Vasiliauskas, {E. A.} and Kam, {L. Y.} and Dubinsky, {M. C.}",
year = "2001",
month = "1",
day = "1",
language = "English",
volume = "4",
pages = "155--164",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Use of serologic tests in Crohn's disease

AU - Abreu, Maria T

AU - Vasiliauskas, E. A.

AU - Kam, L. Y.

AU - Dubinsky, M. C.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Despite great progress in understanding and treating patients with Crohn's disease, the cause of this potentially debilitating disease remains elusive. Multiple studies support the hypothesis that patients with inflammatory bowel disease (IBD) have a dysregulated immune response to endogenous flora. Although we have only 2 labels for patients with IBD, Crohn's disease or ulcerative colitis (UC), these names fall short of describing the pathophysiology of these disease (Figure 1A). We now have a better understanding of the clinical, immunologic, and genetic heterogeneity that exists within "Crohn's diseases" and "ulcerative colitides." Mounting evidence suggests that IBD represents overlapping subgroups of inflammatory intestinal disorders along a continuum, with Crohn's disease and UC representing the extremes of this spectrum (Figure 1). Although the diagnosis of IBD continues to be based on clinical, endoscopic, histopathologic, and radiologic criteria, serologic markers can provide another tool to help diagnose and characterize patients with IBD. Their use is based on the hypothesis that the presence of these antibodies indicates the underlying dysregulated immune response and the environmental trigger, often bacterial, resulting in IBD (Figure 1B). This article will focus on the use of serologic tests to aid in the diagnosis and management of Crohn's disease (Table 1).

AB - Despite great progress in understanding and treating patients with Crohn's disease, the cause of this potentially debilitating disease remains elusive. Multiple studies support the hypothesis that patients with inflammatory bowel disease (IBD) have a dysregulated immune response to endogenous flora. Although we have only 2 labels for patients with IBD, Crohn's disease or ulcerative colitis (UC), these names fall short of describing the pathophysiology of these disease (Figure 1A). We now have a better understanding of the clinical, immunologic, and genetic heterogeneity that exists within "Crohn's diseases" and "ulcerative colitides." Mounting evidence suggests that IBD represents overlapping subgroups of inflammatory intestinal disorders along a continuum, with Crohn's disease and UC representing the extremes of this spectrum (Figure 1). Although the diagnosis of IBD continues to be based on clinical, endoscopic, histopathologic, and radiologic criteria, serologic markers can provide another tool to help diagnose and characterize patients with IBD. Their use is based on the hypothesis that the presence of these antibodies indicates the underlying dysregulated immune response and the environmental trigger, often bacterial, resulting in IBD (Figure 1B). This article will focus on the use of serologic tests to aid in the diagnosis and management of Crohn's disease (Table 1).

UR - http://www.scopus.com/inward/record.url?scp=0035017264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035017264&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0035017264

VL - 4

SP - 155

EP - 164

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 3

ER -